Microbot Medical's LIBERTY System Fuels Over 100% Q2 Revenue & Customer Growth
MBOT sits 27% above its 52-week low of $1.6 on light trading volume (0.3× avg).
Summary
Microbot Medical reported over 100% growth in Q2 2026 revenue and new customers, alongside rising procedure volumes for its LIBERTY Endovascular Robotic System. This significant commercial momentum follows the successful full market release of the LIBERTY system in April and a series of positive developments, including Israeli regulatory approval and a partnership with Lovell Government Services. The substantial growth indicates strong market adoption and execution, which is critical for the medical device company that previously reported Q1 losses and increased cash burn. The company plans to expand U.S. sales territories to 12 and enter international markets by year-end 2026.
At the time of this announcement, MBOT was trading at $2.03 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $129.6M. The 52-week trading range was $1.60 to $4.67. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.